1
|
Christersdottir T, Pirault J, Gisterå A, Bergman O, Gallina AL, Baumgartner R, Lundberg AM, Eriksson P, Yan ZQ, Paulsson-Berne G, Hansson GK, Olofsson PS, Halle M. Prevention of radiotherapy-induced arterial inflammation by interleukin-1 blockade. Eur Heart J 2020; 40:2495-2503. [PMID: 31081038 PMCID: PMC6685328 DOI: 10.1093/eurheartj/ehz206] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/24/2018] [Revised: 04/20/2018] [Accepted: 04/30/2019] [Indexed: 12/15/2022] Open
Abstract
Aims Radiotherapy-induced cardiovascular disease is an emerging problem in a growing population of cancer survivors where traditional treatments, such as anti-platelet and lipid-lowering drugs, have limited benefits. The aim of the study was to investigate vascular inflammatory patterns in human cancer survivors, replicate the findings in an animal model, and evaluate whether interleukin-1 (IL-1) inhibition could be a potential treatment. Methods and results Irradiated human arterial biopsies were collected during microvascular autologous free tissue transfer for cancer reconstruction and compared with non-irradiated arteries from the same patient. A mouse model was used to study the effects of the IL-1 receptor antagonist, anakinra, on localized radiation-induced vascular inflammation. We observed significant induction of genes associated with inflammasome biology in whole transcriptome analysis of irradiated arteries, a finding supported by elevated protein levels in irradiated arteries of both, pro-caspase and caspase-1. mRNA levels of inflammasome associated chemokines CCL2, CCL5 together with the adhesion molecule VCAM1, were elevated in human irradiated arteries as was the number of infiltrating macrophages. A similar pattern was reproduced in Apoe−/− mouse 10 weeks after localized chest irradiation with 14 Gy. Treatment with anakinra in irradiated mice significantly reduced Ccl2 and Ccl5 mRNA levels and expression of I-Ab. Conclusion Anakinra, administered directly after radiation exposure for 2 weeks, ameliorated radiation induced sustained expression of inflammatory mediators in mice. Further studies are needed to evaluate IL-1 blockade as a treatment of radiotherapy-induced vascular disease in a clinical setting. ![]()
Collapse
Affiliation(s)
- Tinna Christersdottir
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.,St. Erik Eye Hospital, Stockholm, Sweden
| | - John Pirault
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Anton Gisterå
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Otto Bergman
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Alessandro L Gallina
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Roland Baumgartner
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Anna M Lundberg
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Per Eriksson
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Zhong-Qun Yan
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Gabrielle Paulsson-Berne
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Göran K Hansson
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Peder S Olofsson
- Cardiovascular Medicine Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Bioclinicum J8:20, Visionsgatan 4, Stockholm, Sweden
| | - Martin Halle
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.,Reconstructive Plastic Surgery, Karolinska University Hospital, Stockholm, Sweden
| |
Collapse
|
3
|
Halle M, Hall P, Tornvall P. Cardiovascular disease associated with radiotherapy: activation of nuclear factor kappa-B. J Intern Med 2011; 269:469-77. [PMID: 21255133 DOI: 10.1111/j.1365-2796.2011.02353.x] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
There have been several recent reports of an increased risk of cardiovascular disease after radiotherapy. Hence, with an increasing number of cancer survivors, the incidence of cardiovascular disease caused by radiotherapy will increase. The existence of a type of vascular disease, or vasculopathy, induced by radiotherapy has been known for decades. It is important to identify and understand the molecular causes of this vasculopathy to determine preventive strategies. Recently, a chronic inflammation with similarities to atherosclerosis has been observed, with activation of the transcription factor nuclear factor kappa-B (NF-κB) as a possible cause. However, the trigger for NF-κB activation is unclear although it may be that reactive oxygen species or direct DNA damage is involved. To minimize the risk of cardiovascular disease in vulnerable patients, careful selection of patients, radiation dose and fractionation are important, together with the development of new techniques that reduce radiation dose to the blood vessels. In the light of the finding of an interaction between risk factors for cardiovascular disease and radiotherapy, it is reasonable to modify these factors including diabetes mellitus, hyperlipidaemia, hypertension and smoking. We believe that preventive strategies focusing on NF-κB can reduce the risk of future adverse cardiovascular events.
Collapse
Affiliation(s)
- M Halle
- Department of Molecular Medicine and Surgery, Section of Reconstructive Plastic Surgery, Karolinska Institutet, Stockholm, Sweden.
| | | | | |
Collapse
|
5
|
Halle M, Gabrielsen A, Paulsson-Berne G, Gahm C, Agardh HE, Farnebo F, Tornvall P. Sustained inflammation due to nuclear factor-kappa B activation in irradiated human arteries. J Am Coll Cardiol 2010; 55:1227-1236. [PMID: 20298930 DOI: 10.1016/j.jacc.2009.10.047] [Citation(s) in RCA: 138] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2009] [Revised: 09/22/2009] [Accepted: 10/27/2009] [Indexed: 12/15/2022]
Abstract
OBJECTIVES The aim of this study was to investigate gene expression networks related to cardiovascular disease in radiated human arteries. BACKGROUND Recent epidemiological studies have shown that radiotherapy is associated with cardiovascular disease years after treatment. However, the molecular mechanisms underlying late effects of radiation are poorly described. METHODS Arterial biopsies from radiated and nonradiated human conduit arteries, from the same patient, were simultaneously harvested during microvascular free tissue transfer for cancer-reconstruction in 13 patients, 4 to 500 weeks from radiation treatment. Radiated and nonradiated arteries were compared, with Affymetrix (Santa Clara, California) microarrays on a subset of the material to generate candidate genes. A Taqman (Applied Biosystems, Foster City, California) low-density array of 45 selected genes was designed for analysis of the whole material. RESULTS Thirteen genes were synchronously expressed in all patients (p = 0.0015), including CCL8, CCL3, CXCL2, DUSP5, FGFR2, HMOX1, HOXA9, IL-6, MMP-1, PTX3, RDH10, SOD2, and TNFAIP3. A majority of differentially regulated genes related to the nuclear factor-kappa B (NF-kappaB) signaling pathway and were dysregulated even years after radiation. The NF-kappaB activation was confirmed by immunohistochemistry and immunofluorescence. CONCLUSIONS In the present study, we found sustained inflammation due to NF-kappaB activation in human radiated arteries. The results are supported by previous in vitro findings suggesting that deoxyribonucleic acid injury, after radiation, activates NF-kappaB. We also suggest that HOXA9 might be involved in the regulation of NF-kappaB activation. The observed sustained inflammatory response can explain cardiovascular disease years after radiation.
Collapse
Affiliation(s)
- Martin Halle
- Department of Molecular Medicine and Surgery, Section of Reconstructive Plastic Surgery, Karolinska Institute, Stockholm, Sweden; Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden.
| | - Anders Gabrielsen
- Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; Department of Medicine, Section of Cardiology, Karolinska Institute, Stockholm, Sweden
| | | | - Caroline Gahm
- Department of ORL, Head and Neck Surgery, Karolinska Institute, Stockholm, Sweden
| | - Hanna E Agardh
- Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden
| | - Filip Farnebo
- Department of Molecular Medicine and Surgery, Section of Reconstructive Plastic Surgery, Karolinska Institute, Stockholm, Sweden
| | - Per Tornvall
- Department of Medicine, Center for Molecular Medicine, Karolinska Institute, Stockholm, Sweden; Department of Medicine, Section of Cardiology, Karolinska Institute, Stockholm, Sweden
| |
Collapse
|